Home /
Our story and philosophy /

News

Strategic cquisition of ALS drives innovation and science at Nuvisan

Featured stories

Close up of business man in suit shaking hands

ALS takes ownership of Nuvisan

With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe. learn more

Nuvisan is the first Gyrolab® Certified CRO in the EU

Nuvisan is the first Gyrolab® certified CRO in the EU

Since March 2024, Nuvisan has become the first Gyrolab® certified CRO in the EU.
learn more

Nuvisan receives $ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines

Nuvisan receives $9.6 million grant

Nuvisan has received a grant from the Gates Foundation for a multi-target drug discovery program. learn more

Other stories

Ribosome facilitating protein synthesis in a biological research study

Nuvisan announces rebranding and web redesign

02 Apr 2025

group pedaling kayak

ALS' strategic acquisition drives innovation and science

27 Jun 2024

Nuvisan is the first Gyrolab® Certified CRO in the EU

Nuvisan is the first Gyrolab® certified CRO in the EU

28 Mar 2024

ALS takes full ownership and control of Nuvisan

ALS takes ownership of Nuvisan

25 Mar 2024

Celebrating Three Years of Fruitful Collaboration: Nuvisan Berlin and Bayer Pharmaceuticals

Three years of fruitful collaboration: Nuvisan Berlin and Bayer Pharmaceuticals

19 Sep 2023

Nuvisan Announces the First Winner of the 1st NUVISAN Drug Discovery Innovation Challenge

Nuvisan announces the first winner of the 1st NUVISAN Drug Discovery Innovation Challenge: ARGO Therapeutics

30 Mar 2023